This would be consistent with impairment of GM-CSF signaling by AUD cells as a contributor to barrier dysfunction due to SARS-CoV-2 and supports the potential for GM-CSF administration as a therapeutic approach in severe COVID-19 (83, 84). The gene discussed is CSF2; the disease is COVID-19.